← Browse by Condition
Medical Condition
myelodysplastic syndrome with excess blasts
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 1
NCT03383575 Phase 2
Recruiting
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Enrollment
63 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT03670966 Phase 1, Phase 2
Recruiting
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Enrollment
30 pts
Location
United States
Sponsor
Fred Hutchinson Cancer Center
NCT06372717 Phase 1
Recruiting
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Enrollment
100 pts
Location
Australia, United Ki...
Sponsor
Apollo Therapeutics Ltd